ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: FR-PO239

Effects of Brazilian Green Propolis Extract on Proteinuria in CKD Patients: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial

Session Information

Category: CKD (Non-Dialysis)

  • 1902 CKD (Non-Dialysis): Clinical, Outcomes, and Trials

Authors

  • Silveira, Marcelo Duarte, University of Sao Paulo School of Medicine, Sao Paulo, SP, Brazil
  • Teles de Farias Filho, Flavio, Federal University of Alagoas, Maceio, AL, Brazil
  • Berretta, Andresa, Apis Flora Indl. Coml. Ltda., Ribeirao Preto, SP, Brazil
  • Rodrigues, Camila Eleuterio, University of Sao Paulo School of Medicine, Sao Paulo, SP, Brazil
  • Sanches, Talita R., University of Sao Paulo School of Medicine, Sao Paulo, SP, Brazil
  • Seguro, Antonio C., University of Sao Paulo School of Medicine, Sao Paulo, SP, Brazil
  • Andrade, Lucia, University of Sao Paulo School of Medicine, Sao Paulo, SP, Brazil
Background

Chronic kidney disease (CKD) is a public health problem of global proportions, and proteinuria is associated with disease progression. Brazilian green propolis (GP) is a natural resin that bees collect from plant sap, presenting anti-inflammatory, immunomodulatory and anti-oxidant properties. We tried to determine whether GP extract can reduce proteinuria and alter the estimated glomerular filtration rate (eGFR).

Methods

This was a randomized, double-blind, placebo-controlled study including 32 patients with diabetic or non-diabetic CKD; between 18 and 90 years of age; with an eGFR of 25-70 ml/min/1.73m2; and with proteinuria (>300mg/day) or micro- or macro-albuminuria (urine albumin-to-creatinine ratio >30mg/g uCr or >300mg/g uCr, respectively). The patients were randomly assigned to receive GP (n=18) or placebo (n=14) at a dose of 500 mg/day and were followed for 12 months.

Results

Proteinuria (mg/24h) was significantly lower in the GP group than in the placebo group—695 (95% CI: 483-999) vs. 1403 (95% CI: 1031-1909)—(p=0.004). This finding was independent of variations in eGFR and systemic hemodynamics, which did not show differences between the groups during the follow-up. There was also a significant reduction of the urinary monocyte chemoattractant protein-1 (pg/mg uCr) was also significantly lower in the GP group than in the placebo group—58 (95% CI: 36-95) vs. 98 (95% CI: 62-155)—(p=0.038). At the dose used, GP was found to be safe and well tolerated.

Conclusion

Our findings broaden the perspectives for the use of GP as a natural adjuvant in reducing proteinuria in CKD. (ClinicalTrials.gov identifier: NCT02766036; Supported by FAPESP)

* P = 0.023; † P = 0.006; ‡ P = 0.004; Propolis vs. Placebo.

Funding

  • Government Support - Non-U.S.